Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $1.53. This compares to a loss of $4.32 per share a year ago.
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to a loss of $2.77 per share a year ago.
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.
Head-To-Head Comparison: Karyopharm Therapeutics (NASDAQ:KPTI) & TransCode Therapeutics (NASDAQ:RNAZ)
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk. Valuation and Earnings This table compares TransCode
Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade
The consensus price target hints at a 56.1% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.23 per share versus the Zacks Consensus Estimate of a loss of $2.26. This compares to a loss of $3.6 per share a year ago.
Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript
Karyopharm Therapeutics Inc. ( KPTI ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Brendan Strong - SVP of Investor Relations & Corporate Communications Richard Paulson - President, CEO & Director Reshma Rangwala - Executive VP, Chief Medical Officer & Head of Research Sohanya Cheng - Executive VP, Chief Commercial Officer & Head of Business Development Lori Macomber - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Bank PLC, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Maurice Raycroft - Jefferies LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Chang - Leerink Partners LLC, Research Division Presentation Operator Good morning.
Karyopharm Therapeutics (KPTI)'s Technical Outlook is Bright After Key Golden Cross
Karyopharm Therapeutics Inc. (KPTI) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KPTI's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $4.32 per share versus the Zacks Consensus Estimate of a loss of $3.8. This compares to a loss of $3 per share a year ago.
